These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1151 related articles for article (PubMed ID: 36125813)
1. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. Xiang B; Zhang R; Wu X; Zhou X JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813 [TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Martin N; Manoharan K; Davies C; Lumbers RT Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072 [TBL] [Abstract][Full Text] [Related]
3. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323 [TBL] [Abstract][Full Text] [Related]
4. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction. Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366 [TBL] [Abstract][Full Text] [Related]
5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095 [TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. Peters AE; DeVore AD Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132 [TBL] [Abstract][Full Text] [Related]
8. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community. Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372 [TBL] [Abstract][Full Text] [Related]
10. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Lin Y; Cai Z; Yuan J; Liu H; Pang X; Chen Q; Tang X; Geng Q; Dong S Cardiovasc Diabetol; 2022 Nov; 21(1):237. PubMed ID: 36348348 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis. Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079 [TBL] [Abstract][Full Text] [Related]
13. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study. Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J; Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622 [TBL] [Abstract][Full Text] [Related]
15. Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA). Rivera-Toquica A; Echeverría LE; Arias-Barrera CA; Mendoza-Beltrán F; Hoyos-Ballesteros DH; Plata-Mosquera CA; Ortega-Madariaga JC; Carvajal-Estupiñán JF; Quintero-Yepes V; Zárate-Correa LC; García-Peña ÁA; Velásquez-López N; Anchique CV; Saldarriaga CI; Gómez-Mesa JE Cardiology; 2024; 149(3):228-236. PubMed ID: 38359813 [TBL] [Abstract][Full Text] [Related]
16. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458 [TBL] [Abstract][Full Text] [Related]
17. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
19. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Dixit NM; Truong KP; Vaduganathan M; Ziaeian B; Fonarow GC JACC Heart Fail; 2024 Jul; 12(7):1226-1237. PubMed ID: 38703159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]